US BANCORP \DE\ - ARROWHEAD PHARMACEUTICALS IN ownership

ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 255 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of ARROWHEAD PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,267,028
-22.6%
47,154
+2.7%
0.00%
-33.3%
Q2 2023$1,638,006
+50.9%
45,934
+7.5%
0.00%
+50.0%
Q1 2023$1,085,672
+49.0%
42,743
+138.0%
0.00%
+100.0%
Q4 2022$728,539
-1.5%
17,962
-19.7%
0.00%
-50.0%
Q3 2022$740,000
+30.7%
22,362
+39.2%
0.00%
+100.0%
Q2 2022$566,000
-29.3%
16,070
-7.7%
0.00%0.0%
Q1 2022$801,000
-26.0%
17,418
+6.5%
0.00%
-50.0%
Q4 2021$1,082,000
+17.4%
16,349
+10.8%
0.00%0.0%
Q3 2021$922,000
-18.3%
14,759
+8.4%
0.00%0.0%
Q2 2021$1,128,000
+34.9%
13,619
+8.1%
0.00%0.0%
Q1 2021$836,000
+141.6%
12,595
+179.4%
0.00%
+100.0%
Q4 2020$346,000
+81.2%
4,508
+1.2%
0.00%
Q3 2020$191,000
-5.0%
4,454
-4.4%
0.00%
-100.0%
Q2 2020$201,000
+44.6%
4,661
-3.7%
0.00%
Q1 2020$139,000
-57.1%
4,841
-5.2%
0.00%
-100.0%
Q4 2019$324,000
+138.2%
5,108
+5.8%
0.00%
Q3 2019$136,000
+10.6%
4,830
+4.8%
0.00%
Q2 2019$123,000
+50.0%
4,608
+2.7%
0.00%
Q1 2019$82,000
+39.0%
4,486
-5.6%
0.00%
Q4 2018$59,000
+742.9%
4,751
+375.1%
0.00%
Q3 2016$7,000
+40.0%
1,0000.0%0.00%
Q2 2016$5,0001,0000.00%
Other shareholders
ARROWHEAD PHARMACEUTICALS IN shareholders Q1 2023
NameSharesValueWeighting ↓
WESTERN FINANCIAL Corp 820,264$54,392,00033.22%
Johnson & Johnson Innovation - JJDC, Inc. 3,260,869$216,228,00028.00%
L1 Capital Pty Ltd 296,024$19,629,0004.93%
Aquilo Capital Management, LLC 407,926$27,050,0004.89%
Evolutionary Tree Capital Management, LLC 72,948$4,837,0002.86%
ACUTA CAPITAL PARTNERS, LLC 108,000$7,161,0002.58%
First Light Asset Management, LLC 536,836$35,598,0002.36%
Parkman Healthcare Partners LLC 70,089$4,648,0001.08%
Hood River Capital Management LLC 357,082$23,678,0000.76%
Vanguard Capital Wealth Advisors 11,099$703,565,0000.60%
View complete list of ARROWHEAD PHARMACEUTICALS IN shareholders